Biohaven (BHVN) Stock Price, News & Analysis

Company Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Key Stats

• Today's Range: $38.92 to $40.82
• 50-Day Range: $35.34 to $42.67
• 52-Week Range: $26.80 to $62.21
• Volume: 88,621 shs
• Average Volume: 867,835 shs
• Market Capitalization: $3.90 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $63.15
• Consensus Rating: Buy

Biohaven Stock Analysis - MarketRank™

Biohaven scored higher than 69% of companies evaluated by MarketBeat, and ranked 322nd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Biohaven has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 14 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Biohaven has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biohaven are expected to grow in the coming year, from ($8.90) to ($6.28) per share.

Price to Book Value per Share Ratio

Biohaven has a P/B Ratio of 7.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.34% of the outstanding shares of Biohaven have been sold short.

Short Interest Ratio / Days to Cover

Biohaven has a short interest ratio ("days to cover") of 9.7.

Change versus previous month

Short interest in Biohaven has recently decreased by 5.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biohaven does not currently pay a dividend.

Dividend Growth

Biohaven does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.34% of the outstanding shares of Biohaven have been sold short.

Short Interest Ratio / Days to Cover

Biohaven has a short interest ratio ("days to cover") of 9.7.

Change versus previous month

Short interest in Biohaven has recently decreased by 5.03%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.99

News Sentiment

Biohaven has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Biohaven this week, compared to 6 articles on an average week.

Search Interest

Only 9 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Biohaven insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,042,260.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

16.00% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BHVN Stock Analysis - Frequently Asked Questions

How have BHVN shares performed this year?

Biohaven's stock was trading at $37.35 at the start of the year. Since then, BHVN shares have increased by 6.5% and is now trading at $39.7690.
View the best growth stocks for 2025 here.

How were Biohaven's earnings last quarter?

Biohaven Ltd. (NYSE:BHVN) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.67) by $0.03.

When did Biohaven IPO?

Biohaven (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Who are Biohaven's major shareholders?

Biohaven's top institutional investors include Vanguard Group Inc. (8.32%), Janus Henderson Group PLC (6.91%), Stifel Financial Corp (6.49%) and Suvretta Capital Management LLC (5.56%). Insiders that own company stock include John W Childs, Vlad Coric, Gregory Bailey, Matthew Buten, George C Clark and Irina Antonijevic.
View institutional ownership trends.

How do I buy shares of Biohaven?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biohaven own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include NVIDIA (NVDA), Humana (HUM), Invesco QQQ (QQQ), Meta Platforms (META), American Water Works (AWK), Broadcom (AVGO) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 3/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:BHVN
• Previous Symbol: NASDAQ:BHVN
• CUSIP: N/A
• CIK: 1689813
• Web: www.biohavenpharma.com
• Phone: 203-404-0410
• Fax: N/A
• Employees: 239
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $63.15
• High Stock Price Target: $76.00
• Low Stock Price Target: $54.00
• Potential Upside/Downside: +58.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.07
• Research Coverage: 15 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($9.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-408,170,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -225.12%
• Return on Assets: -158.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.89
• Quick Ratio: 2.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.34 per share
• Price / Book: 7.45

Miscellaneous

• Outstanding Shares: 101,120,000
• Free Float: 84,942,000
• Market Cap: $4.02 billion
• Optionable: Optionable
• Beta: 1.28